| 2025-04-24 | +4.14 % |
|
| 2025-04-23 | +1.92 % |
|
| 2025-04-22 | +2.22 % |
|
| 2025-04-21 | -2.99 % |
|
| 2025-04-17 | +0.29 % |
|
| 2025-04-15 | -0.38 % |
|
| 2025-04-09 | +14.27 % |
|
| 2025-04-03 | -2.45 % |
|
| 2025-03-27 | -0.22 % |
|
| 2025-03-26 | -2.07 % |
|
| 2025-03-21 | +0.14 % |
|
| 2025-03-20 | -0.05 % |
|
| 2025-03-18 | -0.99 % |
|
| 2025-03-17 | +0.9 % |
|
| 2025-03-10 | -6.88 % |
|
| 2025-03-06 | -5.18 % |
|
| 2025-03-04 | -1.59 % |
|
| 2025-02-24 | -0.13 % |
|
| 2025-02-21 | -2.44 % |
|
| 2025-02-14 | +0.7 % |
|
| 2025-02-12 | -0.34 % |
|
| 2025-02-10 | +2.18 % |
|
| 2025-02-06 | -0.41 % |
|
| 2025-02-04 | +0.19 % |
|
| 2025-02-03 | +1.17 % |
|
| 2025-01-31 | -1.43 % |
|
| 2025-01-30 | +1.3 % |
- Intuitive Surgical, Inc. (ISRG) saw a 1.3% increase in stock price due to optimistic price target revisions from research firms, despite a previous decline attributed to insider selling.
The stock rose as analysts at various firms upgraded their ratings and set higher price targets, indicating positive market sentiment and potential growth for the company.
- Intuitive Surgical, Inc. (ISRG) stock rose 1.3% following a series of positive upgrades from multiple brokerages, with increased target prices and a consensus recommendation of “Moderate Buy” from analysts, which indicates growing investor confidence in the company’s future performance.
- The article discusses the rising mentions of tariffs among corporate executives during earnings calls, highlighting concerns over the potential impacts of trade policies on various industries, including Intuitive Surgical (ISRG), which saw its stock rise by 1.3%. Intuitive Surgical's stock likely increased due to market anticipation and speculation about how it might navigate potential tariff impacts on its manufacturing reliant on Mexico, alongside broader market dynamics around corporate preparations for tariffs and inventory buildup.
|
| 2025-01-28 | +0.12 % |
- Intuitive Surgical's stock (ISRG) rose 0.12% as the company continues to demonstrate significant growth with over 950% increase in the last decade and strong revenue performance attributed to its da Vinci robotic-assisted surgery systems.
- Intuitive Surgical (ISRG) stock rose by 0.12% following the company's Q4 results, which exceeded expectations with a revenue of $2.4 billion and adjusted earnings of $2.21 per share, driven by an 18% year-over-year increase in global da Vinci procedures and the successful launch of its new robotic surgical platform, da Vinci 5.
- The Intuitive Surgical (ISRG) stock rose 0.12% following multiple analysts, including UBS Group and Jefferies Financial Group, raising their price targets, signaling positive investor sentiment and expectations for the company's future performance.
- Intuitive Surgical (ISRG) stock experienced a 0.12% increase, attributed to positive analyst ratings, with several firms raising their price targets and maintaining a consensus rating of "Moderate Buy."
- Intuitive Surgical (ISRG) stock increased by 0.12% following a series of positive price target upgrades from various brokerages, including Jefferies Financial Group raising its target from $475 to $575, which reflects growing bullish sentiment among analysts about the company's future performance.
|
| 2025-01-27 | -1.81 % |
|
| 2025-01-24 | -4.04 % |
|
| 2025-01-23 | -0.29 % |
|
| 2025-01-22 | +1.05 % |
|
| 2025-01-17 | +1.47 % |
|
| 2025-01-16 | +0.68 % |
- Intuitive Surgical (ISRG) stock recently increased due to strong preliminary Q4 sales projections, with a year-over-year growth of 25%, significantly outperforming consensus estimates, mainly driven by the successful launch of the da Vinci 5 system and a rise in total procedure volume.
- Intuitive Surgical (ISRG) stock rose by 0.68% as institutional investments increased, notably with Capital Investment Advisors LLC boosting its stake by 15.6% in the fourth quarter, indicating strong market confidence in the company. This uptick is likely driven by favorable earnings results that exceeded analyst expectations and positive price target adjustments from several brokerages.
- Intuitive Surgical (ISRG) stock increased by 0.68% due to positive analyst upgrades, strong recent earnings performance exceeding expectations, and continued interest from institutional investors.
- The article discusses recent stock activities of Representative Josh Gottheimer, specifically regarding his sale of Texas Roadhouse shares, but does not provide information on why Intuitive Surgical (ISRG) stock rose by 0.68%. The increase in ISRG stock may be attributed to general market trends, company performance, analyst ratings, or investor sentiment, but the article does not specify these reasons.
|
| 2025-01-15 | +7.65 % |
|
| 2025-01-14 | -0.16 % |
|
| 2025-01-13 | -1.41 % |
|
| 2025-01-10 | +0.63 % |
|
| 2025-01-08 | +2.28 % |
|
| 2025-01-03 | +2.15 % |
|
| 2024-12-23 | +0.53 % |
|
| 2024-12-04 | +1.52 % |
|
| 2024-12-03 | -0.21 % |
|
| 2024-11-29 | +0.64 % |
|
| 2024-11-27 | -0.65 % |
|
| 2024-11-18 | +0.76 % |
|
| 2024-11-15 | -1.89 % |
|
| 2024-11-11 | -0.13 % |
|
| 2024-11-08 | +2.32 % |
|
| 2024-10-31 | -1.93 % |
|
| 2024-10-30 | -0.49 % |
- Jim Cramer discussed various stocks including Intuitive Surgical (ISRG), which experienced a decline of 0.49%, although the article does not specify the reasons for this drop.
- Intuitive Surgical (ISRG) stock declined by 0.49% due to potential concerns over slowing growth in the surgical market and market volatility, similar to observed trends in the streaming industry, notably with Netflix's recent challenges in subscriber growth and revenue projections.
- Intuitive Surgical (ISRG) stock declined by 0.49% partly due to the recent sale of 22 shares by Senior Vice President Mark Brosius, which may have raised concerns about insider selling among investors, alongside mixed analyst ratings and varying price target adjustments.
- Intuitive Surgical (ISRG) stock dipped by 0.49% despite significant investment interest, including a notable 288.7% increase in stakes by Creekmur Asset Management, likely indicating broader market influences or profit-taking among investors.
- Intuitive Surgical (ISRG) stock experienced a decrease of 0.49% following the sale of 1,012 shares by EVP Robert Desantis, which could indicate insider selling that often raises concerns among investors.
- Intuitive Surgical (ISRG) stock experienced a decline of 0.49% following the sale of 188 shares by EVP Robert Desantis, which may have raised concerns among investors regarding insider selling.
|
| 2024-10-29 | +1.06 % |
|
| 2024-10-28 | -0.08 % |
- The article discusses the upcoming Q3 earnings report for Eli Lilly, highlighting expected sales growth driven by its diabetes and obesity drugs, but it does not directly address Intuitive Surgical (ISRG) stock. The reason for the slight decline in ISRG stock (-0.08%) is not mentioned in the article.
- Intuitive Surgical (ISRG) stock decreased by 0.08% after SVP Mark Brosius sold 22 shares, likely contributing to negative market sentiment.
- Intuitive Surgical, Inc. (ISRG) stock dipped by 0.08% as FCG Investment Co disclosed acquiring a new stake in the company, purchasing 2,150 shares valued at about $1,056,000, which may have contributed to market fluctuations affecting the stock. The decline could be attributed to broader market dynamics or investor sentiment rather than the specific acquisition.
- The article discusses the recent fluctuations in Monopar Therapeutics' stock price due to a significant licensing agreement, while briefly mentioning that Intuitive Surgical's stock saw a minor decline of 0.08%. The stock of Intuitive Surgical (ISRG) likely went down due to broader market trends or investor focus shifting towards the more dramatic gains of other stocks like Monopar rather than specific negative news about ISRG.
- Intuitive Surgical (ISRG) stock experienced a slight decline of 0.08% amid mixed institutional investment activity, with NorthCrest Asset Management increasing its stake, while various hedge funds adjusted their positions, reflecting broader investor sentiment and market dynamics. The decrease in stock value may be attributed to profit-taking by insiders and the potential volatility seen in tech-related medical stocks over recent trading sessions.
|
| 2024-10-25 | -0.07 % |
|
